ARTICLE

EVALUATION OF PREVALENCE OF COMPLICATIONS OF MEASLES

04 Pages : 34-41

http://dx.doi.org/10.31703/gpsr.2017(II-I).04      10.31703/gpsr.2017(II-I).04      Published : Dec 2017

Evaluation of Prevalence of Complications of Measles

    Study and evaluation of the prevalence of measles and its complication in vaccinated and non- vaccinated patients. To evaluate the prevalence of complications of measles among different age groups of children in the pedriatric ward. Clinical description of a case series. Children of different age groups suffering from measles. We have observed 315 measles patients in the pediatric ward of Bahawal Victoria Hospital in Bahawalpur. They were evaluated on the basis of complications. Different complications were observed in children of different age group and gender, and the main complications were encephalitis, conjunctivitis, pneumonia, diarrhoea and ear infections. Children of age less than 1 year to 7 years were observed, and it was observed that conjunctivitis, pneumonia and diarrhoea were among the most common complications, while encephalitis and ear infections were rare. Patients admitted to the pedriatric ward having long term complications have a high risk of death when treated. These patients were due to malnutrition and improper vaccination coverage, and improper vaccine storage. Respiratory distress, i.e., pneumonia, diarrhoea, conjunctivitis, ear infection and encephalitis, were the most common complications. To reduce the severity of these complications, mechanical ventilation, antibiotics treatment, electrolyte balance should be instituted early in patients with measles.

    Measles, Vaccine, Patients
    (1) Hina Shoukat
    Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Punjab, Pakistan.
    (2) Fahad Pervaiz
    Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Punjab, Pakistan.
    (3) Sobia Noreen
    Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Punjab, Pakistan.
    (4) Ayesha Khadim
    Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Punjab, Pakistan.
    (5) Maira Latif
    Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Punjab, Pakistan.
  • American Academy of Pediatrics, 2009:444-55. Isabel Peña-Rey1,2, *, María Victoria Martínez de Aragón1,2, Odorina Tello Anchuela1,2, Josefa Masa1, Enrique Alcalde Cabero1, María Teresa Castellanos Ruiz1 and Regional Coordinators of the MeaslesElimination Plan#1Servicio de Vigilancia Epidemiológica, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, 28028Madrid, Spain2CIBER Epidemiologia y Salud Publica (CIBERESP), Spain
  • American Academy of Pediatrics. Measles. In: Pickering L, Baker C, Kimberlin D, Long S, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL:
  • Bernstein, D. I., Schiff, G.M., Measles. In: Infectious Diseases, Gorbach SL, Bartlett JG, Blacklow NR (Eds), WB Saunders, Philadelphia 1998. p.1296.
  • Cherry, J. D., Measles, virus. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, et al (Eds), Saunders, Philadelphia 2009. p.2427.
  • Epidemology, & Prevention. of vaccine preventable diseases, The Pink Book:Course Text Book-2th edition 2nd printing (may 2012) )Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis 2004; 189 Suppl 1: S4.BABBOTT FL Jr, GORDON JE. Modern measles. Am J Med Sci 1954; 228:334.
  • Hopkins Bloomberg School of Public Health, Baltimore, Maryland
  • Markowitz, L. E., Preblud, S. R., Fine, P. E., & Orenstein, W. A. (1990). Duration of live measles vaccine-induced immunity.Pediatr Infect Dis J. Feb 9(2),101-[Medline]
  • mumps, & rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998;47(No. RR-8):1-57. (http://www.who.int/vaccines- documents/) http://emedicine.medscape.com/a rticle/966220-medication
  • Robert, T., Perry, 1., & Neal, A. Halsey2 1National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia; 2Department of International Health, Johns
  • Schneider-Schaulies, S., Schneider-Schaulies, J., & Measles. virus-induced immunosuppression. Curr Top MicrobiolImmunol. 2009; 330:243- 69. [Medline].
  • Stephen, J., McPhee, Maxine, A., & Papadakis. (2011). Current Medical Diagnosis and Therapeutics,50th edition, McGraw- hillCompanies,USA.

Cite this article

    CHICAGO : Shoukat, Hina, Fahad Pervaiz, and Sobia Noreen. 2017. "Evaluation of Prevalence of Complications of Measles." Global Pharmaceutical Sciences Review, II (I): 34-41 doi: 10.31703/gpsr.2017(II-I).04
    HARVARD : SHOUKAT, H., PERVAIZ, F. & NOREEN, S. 2017. Evaluation of Prevalence of Complications of Measles. Global Pharmaceutical Sciences Review, II, 34-41.
    MHRA : Shoukat, Hina, Fahad Pervaiz, and Sobia Noreen. 2017. "Evaluation of Prevalence of Complications of Measles." Global Pharmaceutical Sciences Review, II: 34-41
    MLA : Shoukat, Hina, Fahad Pervaiz, and Sobia Noreen. "Evaluation of Prevalence of Complications of Measles." Global Pharmaceutical Sciences Review, II.I (2017): 34-41 Print.
    OXFORD : Shoukat, Hina, Pervaiz, Fahad, and Noreen, Sobia (2017), "Evaluation of Prevalence of Complications of Measles", Global Pharmaceutical Sciences Review, II (I), 34-41
    TURABIAN : Shoukat, Hina, Fahad Pervaiz, and Sobia Noreen. "Evaluation of Prevalence of Complications of Measles." Global Pharmaceutical Sciences Review II, no. I (2017): 34-41. https://doi.org/10.31703/gpsr.2017(II-I).04